Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

BGNE

BeiGene Ltd ADR

Jun 18 • 04:00PM ET

154.70

Dollar change -4.68
Percentage change -2.94	%

Healthcare • Biotechnology • Cayman Islands • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.57	Insider Own	0.92%	Shs Outstand	96.37M	Perf Week	-2.45%
Market Cap	14.91B	Forward P/E	-	EPS next Y	-3.16	Insider Trans	-10.17%	Shs Float	95.49M	Perf Month	-10.50%
Income	-784.43M	PEG	-	EPS next Q	-2.29	Inst Own	47.58%	Short Float	1.64%	Perf Quarter	-7.97%
Sales	2.76B	P/S	5.40	EPS this Y	-0.87%	Inst Trans	-0.41%	Short Ratio	8.84	Perf Half Y	-15.50%
Book/sh	32.13	P/B	4.81	EPS next Y	62.91%	ROA	-13.50%	Short Interest	1.56M	Perf Year	-22.73%
Cash/sh	29.10	P/C	5.32	EPS next 5Y	-	ROE	-20.87%	52W Range	126.97 - 225.23	Perf YTD	-14.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.63%	ROI	-21.93%	52W High	-31.31%	Beta	0.61
Dividend TTM	-	Quick Ratio	1.84	Sales past 5Y	92.60%	Gross Margin	81.47%	52W Low	21.84%	ATR (14)	6.14
Dividend Ex-Date	-	Current Ratio	2.08	EPS Y/Y TTM	59.51%	Oper. Margin	-39.74%	RSI (14)	46.02	Volatility	4.49% 3.54%
Employees	10000	Debt/Eq	0.32	Sales Y/Y TTM	77.42%	Profit Margin	-28.39%	Recom	1.27	Target Price	267.10
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	27.99%	Payout	-	Rel Volume	0.97	Prev Close	159.38
Sales Surprise	12.17%	EPS Surprise	22.11%	Sales Q/Q	67.85%	Earnings	May 08 BMO	Avg Volume	176.80K	Price	154.70
SMA20	-2.44%	SMA50	0.01%	SMA200	-8.63%	Trades		Volume	170,761	Change	-2.94%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-24	Resumed	JP Morgan	Overweight	$185
Sep-12-23	Initiated	Macquarie	Outperform	$259
Aug-17-23	Initiated	Jefferies	Buy	$287
Jul-17-23	Initiated	Citigroup	Buy	$275
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform	$335 → $196
Jan-12-23	Initiated	Daiwa Securities	Buy	$308
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$177 → $200
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$205
Aug-09-22	Resumed	JP Morgan	Overweight	$296
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$300 → $177
Feb-07-22	Initiated	Deutsche Bank	Buy
Oct-12-21	Initiated	Bernstein	Outperform	$431
Oct-06-21	Upgrade	CLSA	Underperform → Buy
Mar-08-21	Initiated	China Renaissance	Buy
Mar-01-21	Downgrade	CLSA	Outperform → Underperform	$330 → $321
Nov-09-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-06-20	Downgrade	Piper Sandler	Neutral → Underweight	$175 → $185
Nov-06-20	Downgrade	Maxim Group	Buy → Hold
Jul-10-20	Downgrade	CLSA	Buy → Outperform
Mar-13-20	Upgrade	Macquarie	Underperform → Neutral

Show Previous Ratings

Jun-14-24 06:00AM	BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 (Business Wire)
Jun-13-24 07:41PM	BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region (Business Wire)
Jun-04-24 06:01AM	BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) +6.05%
May-29-24 07:07AM	7 Large-Cap Stocks That Can Jump 50% By 2025 (InvestorPlace)
May-28-24 08:00AM	BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study (GlobeNewswire)
May-24-24 06:00AM	BRUKINSA Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL (Business Wire)
May-22-24 01:38AM	European Banks M&A Cross-Border Transactions Unlikely, Citi Says (The Wall Street Journal)
May-21-24 09:36PM	Indias Sensex Up 0.2%, Led by Industrial, Consumer Stocks (The Wall Street Journal)
09:36PM	Hong Kong Shares Open Flat; Tech Weakness Persists (The Wall Street Journal)
07:21AM	Glenmark to market BeiGenes oncology medicines in India (Pharmaceutical Technology)
12:33AM	Nikkei Falls 0.3%, Dragged by Real-Estate, Machinery Stocks (The Wall Street Journal)
12:33AM	Hong Kong Shares Extend Losses at Midday Amid Profit Taking (The Wall Street Journal)
May-20-24 01:13PM	BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why (Zacks)
May-14-24 04:01PM	BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 (Business Wire)
May-09-24 01:05AM	Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight (GuruFocus.com)
May-08-24 09:55PM	Indias Sensex Down 0.4%, Dragged by Industrial, Tech Stocks (The Wall Street Journal)
09:55PM	Hong Kong Shares Rise 0.3%, Led by Tech Hardware, Pharma Stocks (The Wall Street Journal)
01:54PM	BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:18AM	Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday (MT Newswires)
06:40AM	BeiGene's Q1 Loss Narrows as Revenue Rises (MT Newswires)
06:00AM	BeiGene Reports First Quarter 2024 Financial Results and Business Updates (Business Wire)
Apr-29-24 09:50AM	10 Most Promising Stocks to Buy Before They Take Off (Insider Monkey)
Apr-26-24 10:34AM	BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report (Business Wire)
Apr-25-24 09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
08:53AM	20 Countries with the Highest Rates of Stomach Cancer in the World (Insider Monkey)
Apr-24-24 04:01PM	Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting (Business Wire)
Apr-23-24 09:19AM	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer (MT Newswires) +6.15%
06:00AM	BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer (Business Wire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 04:28PM	BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy (Business Wire)
02:54PM	UPDATE 1-US FDA approves BeiGene's esophageal cancer therapy (Reuters)
02:14PM	US FDA approves BeiGene's esophageal cancer therapy (Reuters)
Mar-13-24 08:00AM	First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation (Business Wire) +7.77%
Mar-07-24 05:19PM	BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
03:39PM	UPDATE 2-US FDA approves expanded use of BeiGene's blood cancer drug (Reuters)
03:35PM	US FDA approves expanded use of BeiGene's blood cancer drug (Reuters)
01:10PM	Q4 2023 Zymeworks Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-24 06:00AM	BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 (Business Wire)
Feb-29-24 10:00AM	BeiGene Announces New Efficacy Analysis Comparing BRUKINSA vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia (Business Wire) -7.19%
Feb-28-24 08:05AM	BeiGene to Present at Upcoming Investor Conferences (Business Wire)
Feb-27-24 06:00AM	BeiGenes Biologics License Application for TEVIMBRA (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA (Business Wire) +12.12%
12:05AM	Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight (GuruFocus.com)
Feb-26-24 06:32AM	BeiGene Ltd (BGNE) Reports Substantial Revenue Growth and Pipeline Progress in Q4 and Full Year 2023 (GuruFocus.com)
06:00AM	BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (Business Wire)
05:00AM	BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer (Business Wire)
Feb-20-24 10:49AM	BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-13-24 12:58PM	Get Rich Quick With These 3 Biotech Stocks to Buy Now (InvestorPlace)
Feb-07-24 06:47AM	Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma (PR Newswire)
Feb-02-24 05:04AM	10 Blue-Chip Stocks At 52-Week Lows (Insider Monkey)
Jan-31-24 06:47AM	Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib) (PR Newswire)
Jan-23-24 06:00AM	BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors (Business Wire)
Jan-04-24 09:26PM	Chinese Shares Rise, Reversing Opening Losses (The Wall Street Journal) -5.87%
Dec-27-23 08:06PM	12 High Growth International Stocks to Buy (Insider Monkey)
Dec-22-23 06:00AM	FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL) (Business Wire)
Dec-21-23 06:01AM	BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-19-23 11:41AM	13 Most Promising Healthcare Stocks According to Analysts (Insider Monkey)
Nov-30-23 09:55AM	Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet (Zacks)
Nov-29-23 04:01PM	BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023 (Business Wire)
Nov-28-23 06:00AM	BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023 (Business Wire)
Nov-22-23 06:04AM	BeiGene to acquire global license to Ensem Therapeutics' CDK2 inhibitor (Pharmaceutical Business Review)
Nov-21-23 07:14AM	BeiGene stakes out space in hot cancer niche, offering up $1.3B in biobucks for preclinical prospect (FierceBiotech.com)
06:59AM	UPDATE 1-BeiGene to buy global rights to Ensem's experimental cancer therapy (Reuters)
06:14AM	BeiGene agrees to acquire Ensem Therapeutics' cancer therapy (Reuters)
06:00AM	BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor (Business Wire)
Nov-17-23 06:00AM	BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
Nov-15-23 05:05AM	BAKER BROS. ADVISORS LP Bolsters Position in BeiGene Ltd (GuruFocus.com)
Nov-14-23 05:07PM	Health Care Roundup: Market Talk (The Wall Street Journal)
09:55AM	Wall Street Analysts Believe BeiGene, Ltd. (BGNE) Could Rally 32.87%: Here's is How to Trade (Zacks)
Nov-10-23 07:00AM	7 Biotech Stocks to Buy for Big-Time Gains (InvestorPlace) +5.04%
12:22AM	Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight (GuruFocus.com)
Nov-09-23 04:01PM	BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates (Business Wire) -5.32%
Nov-08-23 06:00AM	BeiGene to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-20-23 06:00AM	BRUKINSA Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia (Business Wire)
Oct-17-23 04:01PM	BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
04:01PM	BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Business Wire)
Oct-16-23 06:00AM	BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets (Business Wire)
Oct-13-23 11:51AM	BeiGene Receives Positive CHMP Opinion for BRUKINSA (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma (Business Wire)
Oct-05-23 05:17PM	Ray Dalio on Potential US-China War and Rise of China (Insider Monkey)
Sep-19-23 06:22AM	UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal termination (Reuters)
06:15AM	BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA® (Business Wire)
06:10AM	BeiGene regains rights for cancer drug after Novartis deal termination (Reuters)
06:00AM	BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab) (Business Wire)
Sep-12-23 09:53AM	CVS upgraded, RTX downgraded: Wall Street's top analyst calls (The Fly)
Aug-31-23 07:00AM	BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-17-23 09:39AM	Adobe upgraded, BorgWarner downgraded: Wall Street's top analyst calls (The Fly)
Aug-02-23 06:00AM	BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results (Business Wire) -8.12%
Jul-21-23 07:50AM	BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC (Business Wire)
Jul-14-23 09:58AM	Ray Dalios China Stocks (Insider Monkey)
Jul-13-23 08:12AM	Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation? (Simply Wall St.)
Jul-12-23 07:00AM	BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication (Business Wire)
Jul-10-23 07:00AM	BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors (Business Wire)
Jul-07-23 07:00AM	BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023 (Business Wire)
Jun-15-23 01:20PM	AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent (Benzinga)
08:37AM	BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics (Business Wire)
03:00AM	BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma (Business Wire)
Jun-09-23 03:01AM	BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress (Business Wire)
May-30-23 07:00AM	Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults (PR Newswire)
07:00AM	BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia (Business Wire)
May-25-23 05:05PM	BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio (Business Wire)
02:45PM	Institutional investors are BeiGene, Ltd.'s (NASDAQ:BGNE) biggest bettors and were rewarded after last week's US$813m market cap gain (Simply Wall St.)

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OYLER JOHN	Chief Executive Officer	Apr 11 '24	Sale	146.73	12,084	1,773,085	0	Apr 11 06:01 PM
OYLER JOHN	Chief Executive Officer	Apr 10 '24	Sale	148.89	26,716	3,977,861	12,084	Apr 11 06:01 PM
OYLER JOHN	Chief Executive Officer	Apr 09 '24	Sale	153.94	11,200	1,724,078	38,800	Apr 11 06:01 PM
OYLER JOHN	Chief Executive Officer	Mar 13 '24	Sale	177.56	12,332	2,189,648	0	Mar 14 05:23 PM
OYLER JOHN	Chief Executive Officer	Mar 12 '24	Sale	164.02	37,668	6,178,369	12,332	Mar 14 05:23 PM
Wang Julia Aijun	Chief Financial Officer	Feb 29 '24	Sale	167.08	397	66,331	0	Mar 04 05:22 PM
Lee Chan Henry	SVP, General Counsel	Jul 31 '23	Sale	216.26	791	171,059	0	Aug 02 05:10 PM
Wang Julia Aijun	Chief Financial Officer	Jul 03 '23	Sale	179.55	472	84,747	0	Jul 06 05:02 PM
Wu Xiaobin	President, COO & GM China	Jun 26 '23	Sale	182.37	1,495	272,636	0	Jun 27 05:20 PM
Wang Lai	Global Head of R&D	Jun 26 '23	Sale	181.92	1,108	201,567	0	Jun 27 05:24 PM
Wang Julia Aijun	Chief Financial Officer	Jun 23 '23	Sale	182.85	840	153,594	0	Jun 27 05:22 PM
Sanders Corazon (Corsee) D.	Director	Jun 23 '23	Sale	182.32	578	105,381	0	Jun 27 05:21 PM
Wang Lai	Global Head of R&D	Jun 20 '23	Sale	192.42	1,325	254,955	0	Jun 20 06:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BGNE

BeiGene Ltd ADR

Upgrade your FINVIZ experience